PTSD drug safety study halted early: what we know
NCT ID NCT04468360
First seen Jun 05, 2026 · Last updated Jun 20, 2026 · Updated 2 times
Summary
This small Phase 2 study aimed to test the safety and dosing of an intravenous drug called allopregnanolone (also known as brexanolone) in 11 people with chronic PTSD. The trial was terminated before completion, so results are limited. The main goal was to monitor sedation levels and vital signs, not to measure whether the drug reduces PTSD symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTTRAUMATIC STRESS DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts, 02118, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allopregnanolone (brexanolone)
What this could lead to
If successful, this could help determine safe dosing for future studies testing whether allopregnanolone can improve PTSD treatment.
What could go wrong
This was a very small, early-stage safety study that was terminated. It does not test whether the drug actually helps PTSD symptoms.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.